ArticleDiscover oncology2026
Identification of biomarkers associated with integrated stress response in pituitary adenomas based on bioinformatics.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntegrated stress response (ISR) participates in the development of tumor, however, the roles of ISR-related genes (ISR-RGs) in pituitary neuroendocrine tumor (PitNET) are unclear. The goal of this study was to identify the biomarkers related to ISR-RGs in PitNET and explore their action mechanism.
methodsIn the present study, the public datasets from Gene Expression Omnibus database (GEO) database and ISR-RGs from literature were analyzed to obtain biomarkers for PitNET using differential expression analysis, machine learning algorithm, Boruta analysis and expression validation.
resultsThe results demonstrated that BCL2, ERN1, PMAIP1 and TWIST1, which all possessed significantly lower expression in PitNET samples in training and testing sets, were selected as biomarkers for PitNET. Subsequently, the nomogram showed good performance in predicting PitNET risk based on these biomarkers. BCL2 and PMAIP1 were both validated to locate in Chromosome 18, and BCL2 mainly functioned in cytoplasm and PMAIP1 worked in extracellular region. Additionally, the regulatory networks revealed that biomarkers might work through interacting with BBC3, AC004687, hsa-miR-142-5p, TP53 and STAT3, which provided significant insights into mechanism of biomarkers. Strong correlations were found to exist between activated dendritic cells and TWIST1, as well as between PMAIP1 and T follicular helper cells, which contributed to a more comprehensive understanding of potential immune-related mechanisms. Finally, we totally obtained 36 potential drugs interacting with biomarkers, including sodium arsenite, cyclosporine and valproic acid.
conclusionsThis study identified BCL2, ERN1, PMAIP1 and TWIST1 as biomarkers for PitNET and revealed their action mechanism, which offer potential clues for treatment and study of PitNET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.